Immunogenicity of tick-borne-encephalitis-virus-(TBEV)-vaccination and impact of age on humoral and cellular TBEV-specific immune responses in patients with rheumatoid arthritis

Rack Christoph,Almanzar Giovanni,Schäfer Arne,Völkl Sebastian,Dobler Gerhard,Mutterer Angelika,Schmalzing Marc,Hick Sonja,Steimer Marie,Jahn Lydia,Fladerer Michael,Hartmann Gerhardt,Deininger Frank,Arbogast Martin,Sissy Sonnleitner,Gernot Walder,Feuchtenberger Martin,Prelog Martina
DOI: https://doi.org/10.1016/j.vaccine.2024.01.022
IF: 4.169
2024-01-20
Vaccine
Abstract:Inactivated vaccines, such as tick-borne-encephalitis-virus-(TBEV) vaccine, have been discussed as less immunogenic in elderly and in immunocompromised patients. In this controlled cross-sectional cohort study, the antibody and cellular responses after TBEV-vaccination were investigated in 36 rheumatoid arthritis (RA) patients and 112 healthy controls (HC) by evaluating IgG-anti-TBEV concentration, neutralization and relative avidity index (RAI). Cellular reactivity was assessed by IFNgamma-producing spot-forming-units (SFU) by ELISPOT assay and flow cytometry. RA patients showed lower IgG-anti-TBEV compared to HC, which were influenced by age at and time since last TBEV vaccination and disease duration. High-responders regarding cellular immunity and avidity were less frequent in RA compared to HC. RA patients who had received booster vaccinations were more likely to demonstrate higher IgG-anti-TBEV responses compared to those who had not. In conclusion, RA patients showed a negative effect of age on anti-TBEV-IgG and immunological benefits of timely booster vaccination are suggested.
immunology,medicine, research & experimental
What problem does this paper attempt to address?